Proteomic Investigation of Glioblastoma Cell Lines Treated with Wild-Type p53 and Cytotoxic Chemotherapy Demonstrates an Association between Galectin-1 and p53 Expression

详细信息    查看全文

• 作者：Maja Puchades ; Carol L. Nilsson ; Mark R. Emmett ; Kenneth D. Aldape ; Yongjie Ji ; Frederick F. Lang ; Ta-Jen Liu ; Charles A. Conrad
• 刊名：Journal of Proteome Research
• 出版年：2007
• 出版时间：February 2007
• 年：2007
• 卷：6
• 期：2
• 页码：869 - 875
• 全文大小：1563K
• 年卷期：v.6,no.2(February 2007)
• ISSN：1535-3907

文摘

Global protein analysis of treated and untreatedglioblastoma cell lines was performed. Proteomic analysisrevealed the identity of proteins that were significantlymodulated by the treatment with wild-type TP53 and thecytotoxic chemotherapy SN38. In particular, galectin-1was found to be negatively regulated by transfection withTP53 and further down-regulated by SN38. Expressionlevel changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell linesdemonstrated very high levels of galectin-1, regardless ifthe cell lines contained mutant or wild-type TP53. Highexpression of galectin-1 in a human orthotopic murinetumor model was also detected by immunohistochemistryand revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarrayanalysis in tumor materials from patients confirmedgalectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility ofusing proteomic approaches to interrogate and identifypotential useful targets for cancer therapy by evaluatingspecific tumor responses, either positive or negative, tovarious therapies.